Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol
Recommended Citation
Kutyifa V, Beck C, Brown MW, Cannom D, Daubert J, Estes M, Greenberg H, Goldenberg I, Hammes S, Huang D, Klein H, Knops R, Kosiborod M, Poole J, Schuger C, Singh JP, Solomon S, Wilber D, Zareba W, Moss AJ. Multicenter automatic defibrillator implantation trial-subcutaneous implantable cardioverter defibrillator (madit s-icd): Design and clinical protocol. Am Heart J. Jul 2017;189:158-166.
Document Type
Article
Publication Date
7-1-2017
Publication Title
American heart journal
Abstract
Patients with diabetes mellitus, prior myocardial infarction, older age, and a relatively preserved left ventricular ejection fraction remain at risk for sudden cardiac death that is potentially amenable by the subcutaneous implantable cardioverter defibrillator with a good risk-benefit profile. The launched MADIT S-ICD study is designed to test the hypothesis that post-myocardial infarction diabetes patients with relatively preserved ejection fraction of 36%-50% will have a survival benefit from a subcutaneous implantable cardioverter defibrillator.
Medical Subject Headings
Aged; Death, Sudden, Cardiac; Defibrillators, Implantable; Female; Follow-Up Studies; Humans; Incidence; Male; Myocardial Infarction; Prospective Studies; Survival Rate; Treatment Outcome; United States
PubMed ID
28625372
Volume
189
First Page
158
Last Page
166
